Vivos Begin Period Cash Flow from 2010 to 2025
| VVOS Stock | USD 4.37 0.12 2.82% |
Begin Period Cash Flow | First Reported 2019-09-30 | Previous Quarter 2.6 M | Current Value 6.9 M | Quarterly Volatility 10.4 M |
Check Vivos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 141.3 K, as well as many indicators such as Price To Sales Ratio of 1.2, Dividend Yield of 0.0 or PTB Ratio of 34.88. Vivos financial statements analysis is a perfect complement when working with Vivos Therapeutics Valuation or Volatility modules.
Vivos | Begin Period Cash Flow |
Latest Vivos Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Vivos Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Vivos Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vivos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Vivos Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 4,829,123 | |
| Geometric Mean | 2,995,888 | |
| Coefficient Of Variation | 134.67 | |
| Mean Deviation | 4,072,219 | |
| Median | 2,432,837 | |
| Standard Deviation | 6,503,209 | |
| Sample Variance | 42.3T | |
| Range | 23.6M | |
| R-Value | 0.37 | |
| Mean Square Error | 39T | |
| R-Squared | 0.14 | |
| Significance | 0.16 | |
| Slope | 508,147 | |
| Total Sum of Squares | 634.4T |
Vivos Begin Period Cash Flow History
About Vivos Therapeutics Financial Statements
Vivos Therapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Vivos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 4 M | 3.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.